Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities.
There are currently several ongoing or planned trials evaluating the efficacy of pre-exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.
Kim
Susan C
SC
O'Neill Institute for National and Global Health Law, Georgetown University, Washington, DC, USA. sck3@law.georgetown.edu
Becker
Stephen
S
Dieffenbach
Carl
C
Hanewall
Blair S
BS
Hankins
Catherine
C
Lo
Ying-Ru
YR
Mellors
John W
JW
O'Reilly
Kevin
K
Paxton
Lynn
L
Roffenbender
Jason S
JS
Warren
Mitchell
M
Piot
Peter
P
Dybul
Mark R
MR
D019380:Anti-HIV Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control* / Q000635:transmission*; D006285:Health Planning / Q000191:economics / Q000639:trends; D006801:Humans
D019380:Anti-HIV Agents